ArticleAnnals of hematology2023

CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease.

Yao-Jia Shen et al.PubMed ↗Publisher ↗

No numbers read from the abstract.